Company intelligence / Profile preview
Cycle Pharmaceuticals
- Ownership
- Private
- Employees
- ~100
- Development stage
- Commercial
Overview
Cycle Pharmaceuticals develops and commercializes therapies for rare diseases, focusing on improving orphan drugs, repurposing existing drugs for new indications, and reinstating generics. The company has launched products in the market and maintains a pipeline targeting rare genetic disorders as well as neurological and immunological conditions. It partners with technology providers like Catalent to enhance drug delivery using advanced formulation technologies such as Zydis ODT
- Therapeutic areas
- ImmunologyRare DiseasesNeurologyMetabolic Disorders
- Modalities
- Small moleculeFormulation technology (e.g., orally disintegrating tablets)
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cycle Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cycle Pharmaceuticals.